Newsroom
Featured Press Release
August 27, 2025
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue...
Read more
Press Releases
×
Read
university of washington’s baker lab and google deepmind redefine protein science, paving the way for ai-driven biotherapeutics victoria, british columbia (canada), october 10, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today celebrates the recent nobel prize in chemistry awarded to david baker of the university of washington, seattle, wa, usa, "for computational protein design," and jointly to demis hassabis and john m. jumper of google deepmind, london, uk, "for protein structure prediction." this accolade highlights the vital role of computational tools and ai in advancing our understanding of protein structures—principles that are central to ipa’s research initiatives. these achievements validate the methodologies that underpin ipa’s proprietary foundation ai model, lensai, which leverages similar computational and ai approaches to innovate drug discovery. "as ipa continues to enhance lensai, our proprietary ai platform, we remain committed to leveraging cutting-edge technologies to unravel complex protein interactions. the nobel prize recognition of alphafold underscores the growing importance of ai in scientific breakthroughs. at immunoprecise antibodies, we're dedicated to integrating advanced ai technologies into our workflows, which not only amplifies our capabilities in drug development but also aligns with our mission to pioneer innovative biotherapeutic solutions," said dr. jennifer bath, ceo of immunoprecise antibodies. at ipa, the integration of alphafold, an open-access ai tool developed by google deepmind, into our drug discovery processes has revolutionized how we approach complex biological challenges. by leveraging alphafold's freely available protein structure predictions, ipa enhances the design and optimization of antibodies, making significant strides in developing treatments for diseases that were previously deemed intractable. “our hyft technology amplifies the power of alphafold and other foundational ai models by providing deeper biological context. hyft identifies key functional and structural motifs within protein sequences, enhancing the precision of alphafold's predictions and extending its application in drug discovery, said dr. van hyfte, head of innovation at biostrand. “this combination enables us to push the boundaries of what’s possible in biotherapeutic development, accelerating the path from prediction to solution.” for a deeper dive into alphafold's impact on drug discovery and its integration into ipa's technology stack, explore their subsidiary, biostrand's, blog post: explained: a brief look into alphafold 2. looking ahead, ipa is keen to expand partnerships within academia and industry to further explore ai's potential in developing novel therapies. ipa invites interested parties to join in advancing the application of lensai, aiming for a future where diseases are not merely treated but understood and prevented. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statement this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward–looking statements include, but are not limited to, statements regarding computational and ai approaches to innovate drug discovery. . although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward–looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedar.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.
June 4, 2024
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
dirk van hyfte md, phd, head of technology, ipa, to present live demonstration at the intersystems global summit 2024 june 9-12, 2024 - national harbor, maryland victoria, british columbia (canada), june 04, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its belgian subsidiary, biostrand, is leveraging their patented foundation ai model, lensai, by applying advanced large language models (llm) to capture real world data from electronic health records (ehr). lensai significantly enhances the analysis and integration of ehr data, enabling the integrated use of real-world data and evidence in drug discovery and the development of precision medicines. “ipa’s partners and customers are experiencing impactful results from the lensai next generation, hyft® enabled in silico tools, as they strive to analyze and utilize increasing volumes of rich biological data. these valued partners and customers, as well as potential new users, often encounter challenges with existing omics processing platforms, which struggle to connect diverse datasets. using lensai, ipa has recently demonstrated the ability to generate novel in silico antibodies to challenging diseases where traditional technologies have failed. the ability to efficiently and effectively utilize ehr further strengthens our value proposition”, stated dr. jennifer bath, president and ceo of ipa. "ipa's biostrand group continues to innovate. this model has the potential of dramatically simplifying the connection between real-world evidence and therapeutic discovery and development." said jeff fried, director of platform strategy & innovation at intersystems. "we're proud that they are using intersystems iris; with over 40 years’ experience in ehr integration, the intersystems iris platform is uniquely suited to support biostrand's breakthroughs." positioning ehr as a high-value commodity as tech giants like amazon, microsoft, apple, and alphabet invest heavily in health and wellness, ehrs have become a critical commodity. by integrating ehrs, biostrand enhances its ability to analyze and utilize vast amounts of health data. this capability enables biostrand to deliver superior insights and drive innovation in the rapidly evolving healthcare market. biostrand's business opportunity is centered around leveraging its foundation ai model to drive innovation in drug discovery and precision medicine. the integration of this functionality further strengthens biostrand's ability to scale its operations and expand its market reach, positioning the company as a frontrunner in the biopharmaceutical industry. "the integration of clinical patient data encapsulated in ehr systems within our foundation ai model represents a major step forward," stated dirk van hyfte md, phd, head of technology, ipa (co-founder and head of innovation, biostrand). "this pre-commercial model allows us to leverage extensive patient data, making more informed decisions and accelerating the development of personalized therapies." by invitation, dr. dirk van hyfte will provide a live demonstration to industry leaders and developers at the upcoming intersystems global summit 2024, june 9-12, 2024, in national harbor, maryland. for more details on the event schedule, please visit the summit's website (https://www.intersystems.com/global-summit/). about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: info@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
Read
victoria, british columbia (canada), march 28, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), intersystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with immunoprecise antibodies ltd. (ipa) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. this collaboration integrates the new vector search capability of the intersystems iris® data platform with ipa’s subsidiary biostrand's lensai platform, setting a new standard for ai-driven applications in healthcare and life sciences. this collaboration signifies a leap in technological advancement for addressing challenges with increasing volumes of data that the healthcare and life sciences industries are contending with today. with the global ai market projected to grow to over $1.3 trillion by 2032, the collaboration between intersystems and ipa highlights both companies' commitment to innovation, excellence, and the development of solutions that not only meet the current needs of the healthcare and life sciences sectors but also anticipate future challenges, with additional client solutions and developments expected as vector search and lensai redefine the interaction between data and ai applications in healthcare and life sciences. “as the latest addition to the intersystems iris data platform, vector search has helped to supercharge the identification and creation of novel drug compounds, significantly reducing r&d timelines from development to commercialization” said scott gnau, head of global data platforms at intersystems. “we look forward to seeing how vector search within intersystems iris empowers other developers to build additional ai applications on our platform.” "by combining intersystem’s vector search with ipa's lensai, we're empowering developers and researchers in the life sciences with unparalleled tools for extracting value and insights from complex datasets, driving forward the potential for ai in every application within the healthcare and life sciences sectors," said dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "we are at the cusp of a new era in ai-driven applications, where the integration of sophisticated data analysis tools like vector search with the deep biological insights provided by lensai can lead to breakthroughs in patient care and treatment methodologies.” vector search and lensai: a synergistic integration this innovative integration marries the precision of vector search, which enables efficient and accurate retrieval of relevant information from massive datasets using vector embeddings, with the depth of analysis provided by lensai universal foundation ai model and biostrand's patented hyft technology. the result is a platform that offers unmatched capabilities in accessing, analyzing, and leveraging complex biological data for drug discovery, understanding disease mechanisms, and beyond. advancing healthcare and life sciences the collaboration between intersystems and ipa leverages the strengths of both platforms to offer several transformative benefits: precision and depth in data analysis: the integration enables more precise, semantically rich searches across vast repositories of unstructured biological data, uncovering insights that were previously difficult to obtain. accelerated drug discovery and development: researchers can now leverage the combined power of vector search and lensai to identify novel therapeutic targets more quickly, streamlining the drug discovery process and reducing the time from discovery to clinical trials. enhanced integration and scalability: by providing lensai capabilities within the intersystems iris data platform, companies in healthcare and life sciences gain a tool that seamlessly integrates with their existing infrastructure, offering scalability and enhanced performance without compromising security. about intersystems intersystems is a leading provider of next-generation solutions for enterprise digital transformations in the healthcare, finance, manufacturing, and supply chain sectors. its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. intersystems offers a range of software, including its flagship data platform software, intersystems iris, and a set of industry specific applications that speed and simplify the process of making data “ai ready.” intersystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. privately held and headquartered in cambridge, massachusetts, intersystems was established in 1978 and now has 39 offices in 28 countries worldwide. for more information, please visit intersystems.com. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, healthcare, integration and / or success of lensai with vector search, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology and vector search may not have the expected results, risks that the expected healthcare benefits won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
Read
dirk van hyfte md, phd, co-founder and head of innovation of biostrand, to present findings live next week at the himss24 conference in orlando, florida victoria, british columbia (canada), march 7, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced the development of a foundation ai model that represents a significant advancement in life sciences research and development. the company’s model uniquely combines the strengths of large language models (llms) through an advanced stacking technique with biostrand's patented hyft® technology. the hyft's ability to pinpoint unique 'fingerprints' in biological sequences enables the stacked llms to apply their vast knowledge base with greater specificity, leading to more accurate predictions and insights. this integration marks a pivotal moment in the utilization of artificial intelligence for complex biological data analysis and drug discovery. unveiling the intricacies of hyft technology central to the success of biostrand's foundation ai model is its utilization of its patented hyft technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere. these fingerprints act as critical anchor points, encompassing detailed information layers that bridge sequence data to structural data, functional information, bibliographic insights, and beyond, serving as the great connector between disparate realms of knowledge. biostrand’s platform core is built upon a comprehensive and continuously expanding knowledge graph, mapping 25 billion relationships across 660 million data objects, and linking sequence, structural, and functional data from the entire biosphere to written text such as scientific literature, providing a holistic understanding of the relationships between genes, proteins, and biological pathways. the seamless integration of hyfts with stacked llms enables the biostrand ai model to decode the complex language of proteins, unlocking insights crucial for antibody drug development and precision medicine. large language models (llm), originally developed for natural language processing (nlp), can also be applied on “the language of proteins” enabling insights into tasks including, but not limited to, protein structure prediction, antibody binding optimization, and protein mutagenesis. to understand ‘the language of proteins’, it is essential to detect meaningful words and word boundaries. this is where the hyfts serve as critical enablers. by harnessing hyft's sophisticated computational capabilities, the previously abstract notion of identifying functional units or "words" in protein sequences is made tangible, allowing for precise mapping and analysis. the advanced foundation ai model employs a distinctive approach known as "llm stacking" to intelligently combine different llms, with the hyfts linked to specific features found in various llms. using a natural language analogy, this would mean one is able to distinguish the meaning of ‘apple’ based specifically on the context of the word, in other words, is the word “apple” referring to a type of fruit versus ‘apple’, silicon valley pioneer. in a life sciences context, these features, for example, could include identification of critical amino acid residues involved in protein binding or detecting sequence variations associated with disease susceptibility. the sequence diversity harnessed by the hyfts was discovered during the clustering of next generation sequencing data sourced from ipa’s pipeline subsidiary, talem therapeutics, utilizing the hyft network combined with llm stacking. through the incorporation of various features provided by llm stacking in this study, it was possible to differentiate between binding and non-binding antibodies, even when they shared similar hyft patterns. pioneering a new frontier in life sciences the concept of "word boundaries" within protein languages offers a groundbreaking approach to unlocking the complexities of protein structure and function, filling a void in the knowledge base of researchers and drug developers alike. by enabling precise identification and manipulation of functional units within proteins, this innovative methodology paves the way for advancements in drug discovery, protein-based therapeutics, and synthetic biology. it promises not only to accelerate the development of targeted treatments with higher efficacy and lower side effects but also to revolutionize protein engineering and design. this approach, leveraging cutting-edge computational models and analysis techniques, stands to significantly reduce research and development timelines and costs . advancing drug discovery and precision medicine - lensai ™ integrated intelligence technology™ this methodology revolutionizes biotechnology and pharmaceutical research by providing a robust framework for drug discovery, protein engineering, and the development of protein-based therapeutics. the hyft technology’s application of "word boundaries" is particularly compelling, as it aims to significantly accelerate research and development processes. through the facilitation of targeted treatments and the innovation of novel therapies, the hyft technology offers a reduction in development timelines and costs . by providing a comprehensive understanding of the complex relationships between genes, proteins, and biological pathways, the model paves the way for the development of targeted therapies and personalized treatment strategies. reaffirming biostrand's leadership in biotech innovation "the development of our foundation ai model, powered by our unique 'llm stacking' approach and patented hyft technology, marks a significant milestone in the field of biotechnological research," stated dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "this innovation not only expands the boundaries of current biotech research, but also establishes a new standard for the application of ai in solving complex biological challenges." “as the global community recognizes the transformative potential of artificial intelligence in the life sciences,” dr. hyfte continued, “i am confident that biostrand's foundation ai model will stand at the forefront of innovation and the future of ai-driven solutions in biology and drug discovery.” a future of collaborative discovery in alignment with our mission to foster collaboration and innovation within the life sciences community, we are excited to announce that ipa's ceo, dr. jennifer bath, will participate in the h.c. wainwright 1st annual artificial intelligence based drug discovery & development virtual conference today march 7th, 2024. this participation underscores our commitment to leading the conversation on the future of ai-driven solutions in biology and medicine. additionally, we are thrilled to announce the participation of dirk van hyfte md, phd, co-founder and head of innovation of biostrand, alongside our esteemed technology partner, intersystems, at this year's himss24 conference in orlando, florida. together, we will be showcasing our latest advancements in the field of healthcare technology through intersystems’s innovator introduction program. our presentation will focus on introducing our groundbreaking universal foundation ai model for multiscale biological data integration. we invite you to join us for our lightning pitch session, where we will delve into the capabilities and potential impact of our universal foundation ai model. also, we welcome you to engage in fruitful conversations at intersystem's booth, #1361 at the himss conference, march 12th-14th, 2024. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
Large language models
Sorry. There were no results for your query.